ImmunoGen, Inc. Announces Overall Survival Data Reported For Trastuzumab Emtansine (T

[News]

ImmunoGen, Inc. (Nasdaq: IMGN), a biopharmaceutical company that develops anticancer products using its Targeted Antibody Payload (TAP) technology and antibody expertise, have announced the presentation of overall survival (OS) data from the trastuzumab emtansine Phase III trial, EMILIA...

More... (http://www.medicalnewstoday.com/releases/250934.php)